Introduction
Urogenital cancers, including prostate and bladder cancer, are the most common malignancies and significant causes of morbidity and mortality. Prostate cancer initially responds to androgen deprivation, but can develop hormone-refractory disease that results in progressive deterioration (Goktas and Crawford, 1999) . Invasive bladder cancers are very aggressive and have poor prognosis because of metastatic recurrence after radical surgery . Cisplatin (CDDP)-based chemotherapy has been adopted for these advanced urogenital cancers, although the use of chemotherapy is associated with significant toxicity and provides long-term survival in only 15-20% of patients due to innate or acquired resistance to chemotherapy. To improve chemotherapeutic efficacy, it is important to identify possible target-associated cell-killing mechanisms in urogenital cancer cells.
NADPH:quinone oxidoreductase 1 (NQO1) is a ubiquitous flavoprotein that functions as an antioxidant enzyme (Siegel et al., 2004) . The expression levels of NQO1 are elevated in various kinds of cancers, including liver, breast, colorectal and bladder cancer, compared to the surrounding normal tissue (Danson et al., 2004) . As for its role in cancer, NQO1 is thought to protect cancer cells because it acts as a detoxification enzyme that removes free radicals and makes cells resistant to anticancer agents that induce oxidative injury (Danson et al., 2004) . 3-3 0 -Methylene-bis [4-hydroxycoumarin] (dicoumarol) was characterized as an enzymatic inhibitor of NQO1 and was shown to inhibit proliferation of pancreatic cancer cells through an accumulation of oxidative stress (Madari et al., 2003; Lewis et al., 2004) . In addition, dicoumarol induced p53 degradation through NQO1 inhibition and modulated p53-mediated apoptosis in g-irradiated normal thymocyte (Asher et al., 2001; Anwar et al., 2003) . In the present study, to assess the possibility of NQO1 as a modulator for anticancer agents, we investigated the cytotoxic effects of dicoumarol in combination with CDDP, using cell lines derived from bladder and prostate cancers. Furthermore, the molecular mechanisms underlying cytotoxicity of dicoumarol were analysed.
Results
Expression status of NQO1 protein and sensitivity to dicoumarol in urogenital cancer cell lines In the present study, the effects of dicoumarol were analysed using HNU (human normal urothelial) cells and six urogenital cancer cell lines. NQO1 and p53 status in these cell lines were examined by Western blot analysis and sequencing, respectively. NQO1 was upregulated in all cancer cell lines tested, when compared to the HNU cells: expression levels of protein in each cancer cell line (ratio to HNU cell) were 3.5, 6.9, 8.5, 9.6, 9.8 and 4.6 in RT112, 253J, LNCap, J82, UMUC3 and PC3, respectively. Sequencing analysis confirmed that RT112, 253J and LNCap had wild-type p53, whereas three other cell lines harbored mutant p53: J82 harbored double missense mutations (codon 271, CAG-AAG and codon 320, AAG-AAC), UMUC3 harbored a missense mutation at codon 113 (TTC-TGC) and PC3 contained one base deletion at codon 138. Dicoumarol inhibited cell growth dose-dependently in all six cancer cell lines: IC 50 for dicoumarol were 205.979.6, 210.375.7, 290.3728.7, 127.276.5, 160.478.2 and 176.775 .9 mM in RT112, 253J, J82, UMUC3, LNCap and PC3, respectively, although dicoumarol did not induce apoptosis at a concentration of 100 mM. On the other hand, IC 50 for dicoumarol was 474.7726.0 in HNU cell. Thus, cytotoxic effect of dicoumarol depended on NQO1 expression status, whereas there was no significant association between p53 status and sensitivity to dicoumarol.
Specific enhancement of CDDP-mediated apoptosis by dicoumarol in urogenital cancer cells with wild-type of p53
The effects of dicoumarol on cytotoxicity of CDDP were monitored by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The sensitivity to CDDP was differed among cells: IC 50 were 42.1711.3, 85.876.1, 85.475.2, 969.07106.2, 405.2710.4, 399.1712.0 and 263.6721 .1 mM in HNU cell, RT112, 253J, J82, UMUC3, LNCap and PC3, respectively. Pretreatment of dicoumarol (100 mM) enhanced cytotoxicity of CDDP in RT112 cells by MTT assay (Figure 1a ). Nuclear staining with Hoechst 33342 in RT112 demonstrated that pretreatment with dicoumarol (100 mM) induced apoptosis in combination with CDDP (60 mM) (97.470.9%), although neither CDDP (60 mM) nor dicoumarol (100 mM) alone induced significant apoptosis (19.873.9 nor 3.570.5%, respectively) (Figure 1a ). Similar effects of dicoumarol were identified in 253J and LNCap, which retained wild-type p53, but not in three other cell lines with mutant p53 or HNU cell (Figure 1b and c) . To examine the involvement of NQO1 in dicoumarol-mediated modulation of CDDP cytotoxicity, knock down of NQO1 by small RNA interference approach was performed using 253J cells (Figure 1d ). Western blot analysis confirmed that transfection with an NQO1-specific siRNA oligonucleotide (NQO1-siRNA) decreased the expression of NQO1. MTT assay demonstrated that transfection of NQO1-siRNA led to an increase of sensitivity to CDDP alone, but enhancement of CDDP cytotoxicity by dicoumarol was not observed in 253J with NQO1-siRNA. These results suggested that NQO1 and wild-type p53 were necessary for dicoumarol-mediated modulation of CDDP cytotoxicity.
Pretreatment with dicoumarol suppress the nuclear accumulation of wild-type p53 and induction of p21 To investigate the underlying molecular mechanisms responsible for the effects of dicoumarol on CDDPinduced apoptosis, the expression of p53 and its downstream molecules, p21 and Bax, were assessed by Western blot analysis. In LNCap and RT112 cells, treatment with CDDP alone induced the expressions of p53 and p21 in a time-dependent manner (Figure 2a) . In contrast, pretreatment with dicoumarol suppressed the CDDP-induced accumulation of p53 and sequential induction of p21. Dicoumarol also suppressed the expression of Bax, although the suppressive effects on Bax were weaker than those on p21 (Figure 2a ). On the other hand, neither CDDP nor dicoumarol induced p53, p21 and Bax in J82 cells (Figure 2b) .
To assess the effects of dicoumarol on the intracellular distribution of p53 protein, immunocytochemical examinations were performed using RT112 cells. Single treatment with subtoxic dose of CDDP strongly induced nuclear accumulation of p53, in contrast to the reduction of cytoplasmic staining. On the other hand, pretreatment with dicoumarol decreased the expression of p53 in both the nucleus and cytoplasm (Figure 2c ). Subsequently, we examined the influence of p53 suppression by dicoumarol to cell cycle state by flow cytometry assay. In Figure 2d , cells singly treated with subtoxic dose of CDDP (60 mM) underwent cell cycle arrest at G1 phase after 9 h exposure. In contrast, under combination use of 100 mM dicoumarol and 60 mM CDDP, subpopulation of cells arrested at G1 phase were relatively reduced, and appearance of sub-G1 fraction meaning apoptosis was observed for 9 h exposure. These results suggested that dicoumarol could suppress the p53 activation induced by subtoxic dose of CDDP, and consequently lead the cells to bypass G1-phase arrest.
Involvement of pharmacological suppression of p53 activity in dicoumarol-mediated enhancement of CDDP-induced cytotoxicity Using two stable transfectants (RT112-p53DN-2 and -11) of RT112 cells with p53 dominant-negative mutant (p53DN), CDDP did not significantly induce the expression of p21 and Bax either with or without dicoumarol ( Figure 3a ). Dicoumarol also failed to demonstrate any effects on the cytotoxicity of CDDP (Figure 3b ). These data suggested that p53 status played a critical role in enhancing CDDP-induced apoptosis by dicoumarol.
For further elucidation of p53 involvement, we examined the effect of dicoumarol on cytotoxicity by another anticancer agent, paclitaxel, which was unable to induce p53 accumulation and undergoes its cytotoxicity through p53-independent pathway. Examinations by Western blotting confirmed neither accumulation of p53 nor induction of p21 induced by paclitaxel in RT112 cell line (Figure 3c ). On MTT assay, no enhanced cytotoxicity was observed in paclitaxel-treated RT112 cells regardless of employed dose of dicoumarol, whereas dicoumarol significantly increase the CDDPinduced cytotoxicity by dose-dependent manner. These results might suggest that dicoumarol could enhance CDDP-induced cytotoxicity through wild-type p53.
Dicoumarol enhanced cytotoxicity of CDDP through activated c-Jun N-terminal kinase (JNK) signaling pathway Several p53 downstream genes have recently been reported to regulate mitogen-activated protein kinase (MAPK) cascades (Wu, 2004) . The effects of CDDP and/or dicoumarol on MAPK cascades were investigated by Western blot analysis. Pretreatment with dicoumarol induced phosphorylation of JNK in combination with CDDP, although the expression levels of JNK were not changed ( Figure 4a ). Phosphorylation of JNK and c-Jun at Ser63 was first detected 6 h after treatment with CDDP plus dicoumarol, and was sustained over the following 12 h period in LNCap and RT112 (Figure 4a ). Treatment with CDDP alone or dicoumarol alone did not induce phosphorylation at the same concentration ( Figure 4b ). In contrast, single treatment with CDDP induced phosphorylation of JNK and c-Jun in J82 and RT112-p53DN transfectants. Dicoumarol had no effects on the level of phosphorylation of JNK and c-Jun in these cells (Figure 4b ).
To investigate the significance of activation of JNK in our experiments, RT112 cells were treated with (c) RT112 cells were treated with 60 mM CDDP with or without 100 mM dicoumarol. After 9 h exposure, intracellular locations of p53 were detected as described in 'Materials and methods'. (d) RT112 cells were treated by 60 mM CDDP with or without dicoumarol pretreatment (100 mM). After incubation for 9 h, cells were harvested and stained for DNA with 7-ADD. The rates of population at G1 and sub-G1 (indicating apoptotic fraction) phase are indicated in the figure.
Dicoumarol-mediated enhancement of CDDP cytotxicity J Watanabe et al c-Jun. Combination use of dicoumarol and CDDP suppressed the expression of Bcl-2, and SP600125 inhibited this suppressive effect on Bcl-2. In addition, SP600125 suppressed activation of caspase-8, -9, -3 and poly-(ADP-ribose) polymerase (PARP) cleavage. Similar suppressive effects of SP600125 against cytotoxicity were observed in LNCap, but SP600125 had no influence on J82 and RT112-DN sublines (Figure 5c ). These findings suggested that dicoumarol enhanced cytotoxicity of CDDP through activated JNK signaling pathway in cells with wild-type p53, but no contribution of JNK activation to CDDP-mediated apoptosis in cells harboring p53 mutation.
Discussion
In the present study, we demonstrated that dicoumarol specifically enhanced the cytotoxic effects of CDDP in urogenital cancer cell lines with wild-type p53. Dicoumarol has been reported to have various functions through inhibition of NQO1, including accumulation Dicoumarol-mediated enhancement of CDDP cytotxicity J Watanabe et al of intracellular reactive oxygen species (ROS) (Lewis et al., 2004) or abrogation of p53 protein (Asher et al., 2001; Anwar et al., 2003) . Ubiquitous expression of NQO1 was confirmed in the examined cell lines, and these cells also presented the almost similar sensitivity to dicoumarol. However, the enhancing effects of dicoumarol on CDDP-induced cytotoxicity were absent not only in cells lacking expression of NQO1 but also in cells with mutant p53. These findings indicated that NQO1 and wild-type p53 was essential in dicoumarol-mediated enhancement of CDDP cytotoxicity. P53 is a well-characterized tumor suppressor gene and can induce apoptosis or cell cycle arrest through induction of Bax, Noxa, PUMA and p21 (Vogelstein et al., 2000) . Exposure to CDDP induces p53, leading to cell cycle arrest or apoptosis, although it remains controversial whether wild-type p53 induce or suppress apoptosis in cytotoxicity of CDDP (El-Deiry, 2003) . Human papilloma virus-E6, a well-known p53 abrogator, was reported to enhance cytotoxicity of CDDP in HCT116 colon cancer cells and MCF-7 breast cancer cells, which retained wild-type p53 (Weller, 1998) . Furthermore, in p53 wild-type prostate cancer cell lines including LNCap, it was reported that downregulation of p21 by antisense oligonucleotide enhanced doxorubicin-induced apoptosis (Martinez et al., 2002) . These findings indicated that induction of p53/p21 by CDDP suppressed the apoptotic process, and were consistent with our main results that dicoumarol enhanced cytotoxicity of CDDP through suppression of p53/p21 in urogenital cancer cells.
CDDP also evoked various other signaling pathways including JNK (Mansouri et al., 2003) . As for the mechanism underlying activation of JNK, intracellular ROS production by CDDP is considered to be a possible upstream activator of JNK (Benhar et al., 2001) , whereas p21, a p53 downstream gene, has been reported to suppress activation of JNK (Huang et al., 2003) . In the present study, combination use of dicoumarol and subtoxic dose of CDDP clearly enhanced JNK activation in comparison with single use of CDDP. Furthermore, the specific JNK inhibitor completely inhibited the enhancing effects of dicoumarol on CDDP-mediated cytotoxicity. These findings suggest that dicoumarol might release CDDP-induced JNK activation through a downregulation of the p53-p21 pathway, leading to acceleration of CDDP-induced apoptosis. Dicoumarol-mediated enhancement of CDDP cytotxicity J Watanabe et al Stress-induced activation of JNK has dual functions and can contribute to cell survival as well as apoptosis (Vasilevskaya et al., 2004) . With regard to the role of JNK in cellular response to CDDP, numerous studies have yielded controversial results. In our data, a single use of low-dose CDDP induced sustained JNK activation but did not result in substantial apoptosis in urogenital cancer cells harboring a p53 mutation. Recent studies have displayed that JNK required the mediators to activate caspases, resulting in substantial apoptosis; indispensable role of Bax (Tsuruta et al., 2004) or Fas (Brozovic et al., 2004) apoptotic proteins regulated by p53 at the transcriptional level. In addition, it has been reported that sustained JNK activation could be coupled to hyperphosphorylation and proteosomal degradation on Bcl-2 protein, antagonist for Bax (Yamamoto et al., 1999) . RT112 and LNcap, p53 wild-type cell lines, expressed Bax and the expressions of Bax were not completely suppressed even if cells were treated with dicoumarol and CDDP. On the other hand, p53 mutant cell lines and p53DN transfectants lost the expression of Bax. This lack of expression of Bax, proapoptotic mediator, might be one of the causes for insensitivity for sustained JNK activation in cell lines with mutant p53. Since other signaling pathways including activation of NF-kB or PI3K-Akt pathway antagonize a proapoptotic effect of JNK activation in certain experimental conditions (Yuan et al., 2003; Zhang and Chen, 2004) , it will be interesting to analyse whether mutation of p53 can influence these oncogenic pathways.
In urogenital tumors, mutations of p53 are frequently detected and a relationship between p53 status and chemosensitivity has been extensively examined to date. Although there were conflicting findings on the predictive power of p53 status for chemosensitivity, mutation analysis of p53 demonstrated that tumors with wild-type p53 tended to be resistant to CDDPbased chemotherapy (Cote et al., 1997) . To improve the efficacy of CDDP-based chemotherapy in p53 wild-type urogenital tumors, pharmacological modulation of p53/ p21 expression should be examined as one possible candidate of molecular targeting strategies. Since dicoumarol is already available as an anticoagulant, combined treatment with dicoumarol and CDDP might be feasible and safe compared to in vivo genetic manipulation. Further examinations such as in vivo experimental model concerning safety and efficiency must be indispensable for clinical application of this approach.
In conclusion, dicoumarol sensitized urogenital cancer cells with wild-type p53 to CDDP through suppression of the p53/p21 pathway. Our results will provide a new insight into the anticancer effect of dicoumarol, and the possibility to develop new strategies to overcome chemoresistance to CDDP in urogenital cancers.
Materials and methods

Antibodies and reagents
Antibodies were obtained as follows: anti-JNK, p38, ERK, c-Jun, phospho-JNK, phospho-p38, phospho-ERK, phosphoc-Jun (Ser 63) and caspase-9 from Cell Signaling Technology (Bevery, MA, USA). Anti-caspase-8 from BD PharMingen (San Diego, CA, USA), anti-PARP (C-2-10) from Sigma (St Louis, MO, USA), anti-p53 (Ab-2) from Oncogene Research Product (Cambridge, MA, USA), anti-Bax, Bcl-2, p21 and NQO1 from Santa Cruz (CA, USA) and anti-actin beta from Abcam (Cambridge, MA, USA). SP600125 was from Tocris Cookson Ltd (Bristol, UK). Dicoumarol was obtained from Sigma, and CDDP was from WAKO (Osaka, Japan).
Cell culture
Four bladder (RT112, 253J, J82 and UMUC3) and two prostate (LNCaP and PC3) cancer cell lines were maintained in RPMI1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. HNU cells were isolated from surgical specimens of patient with benign condition as described previously (Southgate et al., 1994) . HNU cells were maintained in keratinocyte serum-free medium and used for experiments at second passage. Cells were incubated at 371C in a humidified atmosphere containing 5% CO 2 .
cDNA sequencing and genotyping of p53 Total RNA was extracted from each cell line using the RNeasy minikit (Qiagen, GmbH, Hilden, Germany) according to the manufacturer's instructions. The cDNA of p53 was amplified by PCR with recombinant Pfu polymerase (Strategene, La Jolla, CA, USA) and directly sequenced using the oligonucleotide primers described previously . The cycle sequencing reactions were carried out using Big Dye Terminator chemistry (PE Applied Biosystems) according to the manufacturer's protocol.
MTT assay
Cytotoxicity was assessed by MTT assay. Briefly, 1 Â 10 4 cancer cells with 100 ml suspension were grown in each well of 96-well plates. After 24 h of incubation, cells were treated with or without different concentrations of drugs for another 24 h. Then, 20 ml of MTT working solution (5 mg/ml; Sigma) was added to each culture well, and incubated for 4 h. The formazan crystal was dissolved with 100 ml DMSO. The absorbance (A) of each well was measured by a microculture plate reader (Immunoreader; Japan Intermed Co., Ltd, Tokyo, Japan) at 540 nm. The percentage of cytotoxicity ¼ (1À(A of experimental wells/A of control wells)) Â 100.
Plasmid and transfection pCMV-neo was a gift from Dr K Cho (University of Michigan Medical School). p53DN containing one missense mutation at codon 135 (TGC-TAC), which were purchased from BD Bioscience, were ligated into pCMV-neo. RT112 cells were transfected with pCMV-neo or pCMV-p53DN by using LipofectAmine (Life Technologies Inc., Grand Island, NY, USA) following the manufacture's instructions. Two stable transfectants (RT112-p53DN-2 and RT112-p53DN-11) were obtained by selection for G418 resistance (800 mg/ml). Overexpressions of p53DN were confirmed by sequencing and Western blot analysis.
siRNA and transfection 253J cells were plated at 6 Â 10 4 /60 mm plate. A measure of 20 ml of 20mM siRNA targeting exon 6 (sense, 5 0 -GCCU CUCCGACCUAAACUUtt-3 0 ; antisense, 5 0 -AAGUUUAG GUCAAAGAGGCtg-3 0 ; Ambion Inc., Austin, TX, USA) of human NQO1 were mixed with 340 ml OPTI-MEM (Invitrogen, Carlsbad, CA, USA). In parallel, 8 ml OligofectAMINE (Invitrogen) was mixed with 32 ml OPTI-MEM. After 10 min incubation, the two solutions were mixed, incubated for more 20 min at room temperature. Finally, this combined mixed solution was added to the plates. After 24 h, cell lysates were prepared to examine the expression of NQO1. On the other hand, cells were treated with 40 mM CDDP with or without 200 mM dicoumarol, and cytotoxic effects of these treatments were examined.
Drug treatment and preparation of cellular extracts
For the dose-response and the time-course studies, cells were grown to 70-80% confluency in 100 mm dishes for 48 h. Cells were then treated for appropriate times with different concentrations of CDDP with or without dicoumarol. For analysis of JNK pathway, cells were treated with 40 mM of SP600125 dissolved in DMSO and dicoumarol following the exposure of CDDP. After treatment, cells were washed with phosphate-buffered saline (PBS) and lysed in an appropriate volume of ice-cold cell lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin) supplemented with 1 mM phenylmethylsulfonyl fluoride. Cellular lysates were clarified by centrifugation at 13 000 g for 15 min. Portions of the same cellular extracts were used for Western blot analysis.
Western blot analysis
In all, 40 mg of total protein lysate were separated by SDS-PAGE on a 10-15% Tris-HCl minigel, and transferred onto a PVDF membrane following standard methods. After blocking of the membrane, primary antibodies were incubated for 16 h at 41C and horseradish peroxidase-conjugated secondary antibodies were added for 1 h. Proteins were visualized by the chemiluminescent detection system.
Flow cytometric analysis RT112 cells after treatment with 60 mM CDDP with or without 100 mM dicoumarol were harvested at different time points, and were stained with 7-amino-actinomycin D (7-ADD, BD Biosciences, San Diego, CA, USA). Flow cytometry was performed on a FACScan (Becton Dickinson, San Jose, CA, USA). For staining, cells (1 Â 10 6 ) were harvested, washed with ice-cold PBS and then fixed in 70% ethanol. Fixed cells were treated with DNase-free RNase for 30 min at 371C, washed with PBS, centrifuged and incubated in PBS containing 7-ADD (5 mM). Cell cycle distribution was analysed using Cell-Quest software (Becton Dickinson).
Immunocytochemical studies RT112 cells were grown and treated with 60 mM CDDP with or without 100 mM dicoumarol for 9 h in chamber slides. For permeabilization and fixation, cells were treated with methanol at À201C for 10 min. Cells were washed and blocked with 10% serum containing PBS, and then primary antibody was added. Finally, FITC-conjugated secondary antibody was added, and cells were visualized using a Nikon Eclipse E1000 (Nikkon, Tokyo, Japan) and photographed with DC300FX digital camera and IM1000 software (Leica Microsystems Digital Imaging, Cambridge, UK).
Detection of apoptosis
To detect apoptosis, nuclear staining was performed using 1 mM Hoechst 33342 solution (Wako, Osaka, Japan) and cells were analysed with a fluorescence microscope. Apoptotic cells were identified by morphology and by condensation and fragmentation of their nuclei. The percentage of apoptotic cells was calculated as the ratio of apoptotic cells to total cells counted.
